The biotechnology sector is currently at a strategic crossroads, marked by the increasing integration of artificial intelligence (AI) and innovations in personalized therapies. However, it faces major structural challenges, particularly the "patent cliff," which threatens to reduce industry revenues by $400 billion. This massive patent expiration is pushing companies to innovate rapidly to offset revenue losses. The convergence of AI and biotechnology offers unprecedented opportunities but also raises ethical and security concerns, particularly regarding intellectual property and cyber risks.